Methods overview. To disentangle the causal and tagging gene-trait associations at a TWAS-significant region, we analytically derive the covariance structure among TWAS statistics as a function of LD and eQTL weights used in prediction. Next, we model the entire Transcriptome-wide association studies using predicted expression have identified thousands of genes whose locally regulated expression is associated with complex traits and diseases. In this work, we show that linkage disequilibrium induces significant gene-trait associations at non-causal genes as a function of the expression quantitative trait loci weights used in expression prediction. We introduce a probabilistic framework that models correlation among transcriptome-wide association study signals to assign a probability for every gene in the risk region to explain the observed association signal. Importantly, our approach remains accurate when expression data for causal genes are not available in the causal tissue by leveraging expression prediction from other tissues. Our approach yields credible sets of genes containing the causal gene at a nominal confidence level (for example, 90%) that can be used to prioritize genes for functional assays. We illustrate our approach by using an integrative analysis of lipid traits, where our approach prioritizes genes with strong evidence for causality.
T ranscriptome-wide association studies (TWASs) using predicted expression levels have been proposed as an approach to identify novel genomic risk regions and putative risk genes involved in complex traits and diseases [1] [2] [3] . Since TWAS based on predicted expression relies on only the genetic component of expression, it can be viewed as a test for non-zero local genetic correlation between expression and trait 1, 4, 5 . Significant genetic correlation in this setting is often interpreted as an estimate of the effect of SNPs on a trait mediated by the gene of interest. However, this interpretation requires very strong assumptions that are probably violated in empirical data due to linkage disequilibrium (LD) and/or pleiotropic SNP effects [1] [2] [3] [6] [7] [8] [9] [10] [11] . Therefore, TWAS has been mostly utilized as a test of association, in contrast to methods that attempt to directly estimate the mediated effect (that is, Mendelian randomization 3, [6] [7] [8] [9] ). In this work, we show that the gene-trait association statistics from TWAS at a known risk region are correlated as a function of LD among SNPs and expression quantitative trait loci (eQTL) weights used in the prediction models. The effect is similar to LD tagging in genome-wide association studies (GWASs) where LD within a region induces associations at tag SNPs (yielding the traditional Manhattan-style plots). Even in the simplest case where a single SNP causally impacts the expression of a gene, which in turn causally impacts a trait, LD among SNPs used in the eQTL prediction models induces significant gene-trait associations at nearby non-causal genes in the region. The tagging effect is further exacerbated in the presence of multiple causal SNPs and genes. As an illustrative example, consider a risk region with six genes where a single SNP is causal for a single gene which impacts the trait (Fig. 1 ). Although genes 3 and 4 in Fig. 1 have non-overlapping prediction weights due to different eQTL genetic regulation, LD among SNPs with non-zero prediction weights induces correlations in the TWAS statistics at genes 3 and 4. Estimating the correlation structure of predicted expression among nearby genes enables statistical fine-mapping over genetrait associations. However, several confounding factors can bias inference. First, there is a body of evidence supporting horizontal pleiotropic effects from SNPs 8, 11, 12 , which bias gene-trait association statistics. Second, it is critical that TWAS fine-mapping approaches maintain robustness when the causal mechanism is not steady-state levels of gene expression 10 . Fine-mapping in these instances without controlling for confounding could prioritize non-causal genes.
Here, we propose an approach to perform statistical finemapping over the gene-trait association signals from TWAS. Our approach, FOCUS (fine-mapping of causal gene sets), accounts for the correlation structure induced by LD and prediction weights used in the TWAS and controls for certain pleiotropic effects. FOCUS takes as input GWAS summary data, expression prediction weights (as estimated from eQTL reference panels), and LD among all SNPs in the risk region, and estimates the probability for any given set of genes to explain the TWAS signal. We extend probabilistic SNP fine-mapping approaches [13] [14] [15] to estimate sets of genes that contain the causal genes (defined here as a gene responsible for the association signal) at a predefined confidence level (that is, ρ-credible gene sets). We perform extensive simulations and show that FOCUS is approximately unbiased in estimating the posterior probabilities and credible sets at a specified certainty when the causal gene is present in the data. When the causal tissue is unavailable and alternative tissues with correlated expression levels are used as a proxy, FOCUS maintains its performance under standard assumptions. Finally, as a demonstration using real GWAS data, we apply FOCUS to four GWASs of lipid levels 16 . We find that FOCUS prioritizes genes with established roles in low-density lipoprotein (LDL) risk (for example, SORT1) 17 .
vector of marginal TWAS association statistics (z twas ) at all genes in a region (TWAS significant and not-significant), using a multivariate Gaussian distribution parameterized by the effect sizes at causal genes (λ pe ), residual SNP effects (λ snp ), and the correlation structure induced by inferred expression weights (Ω) with LD (V) as
twas snp pe T snp T pe T (see Methods). We control for bias resulting from pleiotropic effects of SNPs by including an intercept term that quantifies the average SNP effect sizes (λ snp ) tagged by predicted expression (Ω λ V T snp ; see Methods). To allow for genes without prediction models in the relevant tissue (due to quality control and/or low power in eQTL studies), we leverage recent work demonstrating that eQTLs are largely shared across tissues 18 and include prediction models from proxy tissues for such genes (see Methods). We employ a standard Bayesian approach to compute the marginal posterior inclusion probability (PIP) for each gene in the region to be causal given the observed TWAS statistics. To avoid overfitting, we integrate out the unknown causal effects λ pe using a multivariate Gaussian prior (see Methods). We use PIPs to compute ρ-credible gene set that contain the causal gene with probability ρ (refs. [13] [14] [15] ). To account for missing causal mechanisms, due to either unpredicted expression or other latent functional mechanisms, we include the null model as a possible outcome in the credible set, which acts as a regularization for posterior estimates at observed genes (see Methods). Lastly, we use a simulation-based procedure to compute posterior predictive checks 19 that measure the FOCUS model's goodness-of-fit given observed TWAS Z-scores.
FOCUS yields accurate credible sets in simulations.
To characterize the predicted expression correlation structure and to validate our framework, we used extensive simulations starting from real genotype data to generate expression reference panels and GWAS summary data ( Fig. 2 ; see Methods). We confirmed that non-causal genes in risk regions show significant association with trait as a function of LD and eQTL weights (see Supplementary Fig. 1 ), which motivates TWAS fine-mapping to prioritize genes causally impacting trait 10 . We simulated complex traits under a variety of architectures to assess the performance of 90%-credible gene sets computed using FOCUS ( Fig. 3 ; see Methods). When the causal gene was assayed in its relevant tissue, we found that 90%-credible gene sets contained 83% (s.d. 0.04) of causal genes across simulations on average ( Fig. 3 and Supplementary Fig. 2 ). FOCUS models an intercept term to control for pleiotropic SNP effects (λ snp ) tagged through predicted expression. In simulations where SNPs directly impacted downstream trait, we found a small decrease in performance ( Fig. 3 ; see Methods), which suggests that FOCUS maintains performance despite regressing out the average local effect. Next, we varied sample size across GWAS and reference eQTL data sets. Intuitively, we found improved performance for FOCUS to detect causal genes as sample size increased ( Fig. 3 and Supplementary Fig. 3 ). Sample size for the eQTL reference panel affected performance to a larger degree than GWAS sample size, consistent with earlier reports 1 . For example, at N eQTL = 100, we found that 90%-credible gene sets contained the causal gene in 76% of simulations, which is significantly lower when compared with 84% for N eQTL = 500 (Mann-Whitney U-test P = 2.52 × 10
−6
). Next, we explored how underlying heritability of expression at causal genes impacts prioritization. Heritability defines the prediction upper bound for SNP-based approaches 20, 21 , and we expect performance to improve as non-zero heritability is easier to detect. We confirmed that performance increased with heritability of causal gene expression (Fig. 3) . For example, we simulated gene expression having heritability = .
h 0 01 g 2 and inferred eQTL weights using N eQTL = 500 and found a significant decrease in performance when compared with = .
h 0 2
). We investigated the role of the prior effect-size distribution for gene expression 4, 22 and found performance to remain stable for a wide range of values ( Supplementary Figs. 4 and 5) . Lastly, similar results were obtained when using sparse regression to predict gene expression ( Supplementary Fig. 6 ) and when using an alternative FOCUS model to account for variation across pleiotropic effects (Supplementary Note and Supplementary Fig. 7 ).
FOCUS remains stable when using proxy tissues. Next, we investigated the performance of FOCUS when the causal gene in the relevant tissue is missing but is measured in a different tissue (see Methods). In real data, a gene may act through a tissue that is difficult to assay in large sample sizes but may have similar cisregulatory patterns in tissues that are easier to collect (for example, blood). Indeed, several studies 1, 4, 18, 23 established that cis-regulated gene expression levels exhibit high genetic correlation across tissues and functional architectures. The intuition in this approach is that the loss in power from using the correlated tissue is offset by the gain in power due to larger eQTL sample size. Here, we consider a causal gene to be successfully fine-mapped if its corresponding proxy tissue model is in the 90%-credible gene set. When sample sizes for eQTL in the relevant and proxy tissues were the same, but heritability in proxy tissue was lower than in the relevant tissue, we found a significant loss in accuracy. We found that 90%-credible sets captured the causal gene in 75% ; Fig. 3 ). This effect was not observed when heritability of proxy tissue gene expression was at least that of expression in the relevant tissue (Mann-Whitney U-test P = 0.27). For example, when expression in the relevant tissue was = .
in the proxy, we found that 90%-credible gene sets contained the causal gene in significantly fewer simulations (64% versus 83%; Mann-Whitney U-test P = 8.6 × 10
−7
). This suggests that when causal eQTLs are shared across tissues, increased heritability of expression increases power to detect the causal gene. In our simulations we found correlation of effect sizes at shared eQTLs to play no major role in performance when heritability of expression in the relevant and proxy tissue was similar ( = .
h 0 2 g 2 ; Fig. 3 and Supplementary Fig. 8 ). In the case of zero correlation between effect sizes at the same eQTL SNPs, this result can be interpreted as pleiotropic effects on independent molecular traits, which are known to be difficult to differentiate from a causal effect 1, 3, 8 . However, we note that this result could be impacted by the simulation setup that enforces 1-2 eQTL SNPs as causal across tissues. Collectively, these results demonstrate that FOCUS is relatively robust to model perturbations and performs well when underlying tissue-specific causal genes are represented by proxy tissue eQTL weights.
FOCUS is robust to confounding.
We have shown that TWAS statistics are correlated due to LD between eQTL SNPs, implying that when predicted expression for the causal gene is not included in the inference, nearby genes will probably be prioritized in finemapping. FOCUS controls for this scenario by explicitly modeling the null (that is, causal configuration c = 0; see Methods) as a possible explanation when computing credible gene sets. We tested the performance of FOCUS in standard-null simulations, when there is no relationship between expression and trait, and found that the null model was contained in the 90%-credible gene set in 2,495 of 2,500 of our simulations. On average, 90%-credible sets contained 3.4 models (including the null) and 2.4 when restricted to genes only. In 298 of 2,500 simulations, the null model was the only model defining the 90%-credible gene set. For the remaining 2,202 of 2,500 credible gene sets, the average posterior probability ). Together, these results indicate that FOCUS is accurate when no relationship between gene expression and trait exists. We next performed experiments using simulations where causal gene expression impacts the downstream trait but has been masked from the data before testing. We found the null model in 69% (s.d. 0.07) of 90%-credible gene sets (Fig. 4) ). Altogether, we find that FOCUS is robust in the challenging setting of prioritizing the null model when causal expression is missing.
Next, we investigated simulations in which there is no mediated effect of steady-state gene expression on downstream trait, but eQTLs for genes have pleiotropic effects on downstream trait (that is, pleiotropic eQTLs). Here, we measured performance by counting how often the null model was prioritized over corresponding regional genes for each risk region in the pleiotropy simulations. Overall, we found that the null model was the top-ranked model for 251 of 500 regions (Fisher's exact P < 2.2 × 10
−16
). Similarly, the 90%-credible gene sets within pleiotropic eQTL simulations were enriched with null model capture (328 of 500 sets; Fisher's exact P < 2.2 × 10
). We next compared performance across simulation types. We focused on credible sets that contained the null model and computed the average posterior probability in pleiotropic eQTL simulations and standard simulations. The credible gene sets contained the null model in a larger fraction of regions compared with those from standard simulations (Fig. 4) . Similarly, focusing on the null models captured in credible sets, pleiotropic eQTL simulations resulted in more posterior density being assigned to the null model compared with those from standard simulations (Mann-Whitney U-test P = 0.04). Together, these results imply that FOCUS prioritizes the null model in the majority of simulated scenarios where SNPs exhibit a horizontal pleiotropic effect. Lastly, we performed simulations in which a non-causal gene shares the same regulatory eQTL as the causal gene. We found computed PIPs to be similar between the causal and non-causal in this eQTL scenario, reflecting the challenge in discerning causality when regulatory variants are shared across genes ( Supplementary Fig. 9 ).
FOCUS improves resolution for fine-mapping causal genes.
Having established that causal genes are contained in the credible set, next we quantified the average number of genes captured. We found that 90%-credible gene sets contained 4.4 genes on average (s.d. 1.3) in the relevant-tissue simulations, which resulted in an average 54% of predicted genes per risk region. We found a similar number of genes in 90%-credible gene sets across simulations when varying model parameters and sample sizes ( Supplementary Figs.  10-15 ). For completeness, we prioritized genes in simulations using 90%-credible gene sets for direct comparison with TWAS P values and the posterior probability of colocalization (COLOC PP4 (ref.
)).
In detail, we simulated a complex trait where multiple genes in a region are causal and each gene has multiple eQTLs (see Methods). We then selected genes in two ways. First, we selected the same number of genes using either P value or PP4 ranking as the 90%-credible gene set (listed as 'matched'). Second, we selected genes using standard thresholds for COLOC (PP4 ≥ 0.8) and TWAS P value (P < 0.05/15,277). We found that prioritizing genes by using credible sets outperformed both alternatives (Fig. 5 (Fig. 5) . Relative performance for FOCUS improved when comparing with non-size-matched methods (Fig. 5) . Similarly, using relaxed thresholds to determine colocalization (PP4) showed comparable results (Supplementary Table 1 ). Overall, we find that FOCUS has greater sensitivity to identify causal genes across realistic simulations. Application to lipid GWAS. Next, we re-analyzed a large-scale GWAS of lipid measurements 16 with eQTL weights from adipose tissue. We assumed that the relevant tissue for expression driving lipids is adipose tissue, given its well-characterized role [25] [26] [27] [28] . To account for missing gene prediction models, we incorporated gene expression models for genes not predictable from adipose tissue across 45 tissues measured in 47 reference panels. In detail, for a gene without a predicted model in adipose tissue, we included the prediction model with the best accuracy across all other tissues (Supplementary Table 2 ; Prediction models were trained using the relevant (that is, causal) tissue. Box-plots represent the median, upper and lower quartiles, and 1.5× interquartile range of the total number of genes captured in the 90%-credible gene sets over simulations. b, Method sensitivity in capturing causal genes in simulations. We ranked genes based on their P value (TWAS; P < 0.05/15,277) or colocalization score (PP4 ≥ 0.8). We also selected the same number of ranked genes as the 90%-credible gene set (matched). 'Standard' refers to simulations in which eQTLs are sampled for each gene. 'Shared' refers to simulations in which eQTLs are sampled and shared among all genes. 30 that found 25% overlap between GWAS and eQTL at risk regions (Table 1) . Of the 75 trait-region pairs with a significant TWAS association, 47 had multiple significant TWAS associations, thus motivating our fine-mapping approach.
We next applied FOCUS at the 75 GWAS risk regions with evidence for regulatory action on genes driving lipid levels to compute PIPs and estimate credible sets of genes at each of the regions (see Methods). We found that observed risk regions can be explained by 1.5 causal genes on average, with 61 of 75 risk regions containing fewer than 2 causal genes in expectation ( Supplementary  Figs. 20 and 21) . The average maximum PIP across credible sets was 88% (and decreased exponentially for lower ranked genes; Supplementary Fig. 20) . Together, these results imply that most risk regions can be explained by a single causal gene. Using computed PIPs, we estimated 90%-credible gene sets for each risk region and found a significant reduction in the number of prioritized genes (mean 1.9) compared with transcriptome-wide-significant genes (mean 3.2; Mann-Whitney U-test P = 7.24 × 10 −4
; Supplementary Table 4) . We compared the sensitivity of FOCUS to the setting of the prior variance term (σ c 2 ) and found computed PIPs to be highly similar across lipid traits (t-test P < 2.2 × 10 −16 ; Supplementary Fig.  22 ). Comparing FOCUS results with those of TWAS ranking, we found that in 47 of 75 total trait-region pairs, the gene with the highest TWAS Z-score was also the gene with the highest PIP. When excluding the null model, this proportion increased to 57 of 75. As a positive control, we examined the 1p13 locus for LDL, as this region harbors risk SNP rs12740374 (NC_000001.10:g.109817590 G>T) which has been shown to perturb transcription of the SORT1 gene and impact downstream LDL levels 17 . We found 4 of 34 genes included in the 90%-credible set, of which SORT1 had a posterior probability 95% (Fig. 6 and Supplementary Table 5) .
Finally, we investigated regions whose 90%-credible gene sets contained the null model (that is, regions with weaker evidence for models of gene expression driving risk). An instance that contains the null model in its credible set may be partially consistent with the observed association between expression levels and trait being due to chance. We found 25 of 75 instances of the null model captured in credible sets for lipid traits (Supplementary Table 4) , which suggests that most overlapping GWAS risk regions are more consistent with risk contributed from cis-regulated expression levels, compared with statistical noise explaining observed signal. PIP output by FOCUS are conditioned on the FOCUS model being correct. If the FOCUS model does not accurately capture the underlying generative process, then PIPs will be biased. We used a simulation procedure (see Methods) to quantify model fit for each gene and found that the FOCUS model largely agreed with observed data (that is, TWAS Z-scores; see Supplementary Fig. 23 ).
Discussion
In this work we presented FOCUS, a fine-mapping approach that estimates credible sets of causal genes by using prediction eQTL weights, LD, and GWAS summary statistics. We demonstrated that FOCUS prioritizes the null model in null simulations and is accurate in identifying causal genes when genes at a region impact downstream trait. We found 90%-credible gene sets to be largely stable across a variety of simulations, with the biggest impact in performance due to eQTL reference panel sample size and SNPheritability of gene expression. We applied FOCUS to four lipid TWASs (for example, high-density lipoprotein (HDL), LDL, triglyceride, and total cholesterol levels) and found that SORT1 was correctly identified as a putative causal gene. Interestingly, our realdata results in lipids suggest that most regions can be explained by a single causal gene. Overall, our results highlight the utility of using credible sets in prioritizing causal genes by jointly assigning posterior probabilities, which are both easily interpretable and comparable across genes and regions.
In addition to providing a quantification of the confidence in how many genes need to be validated to identify the causal genes in the region, our probabilistic approach yields several benefits. First, FOCUS naturally allows for multiple causal SNPs and genes while integrating gene-effect sizes by using conjugate priors; this is particularly important, as recent works have shown that allelic heterogeneity (that is, multiple causal genes and SNPs at a region) is pervasive in both eQTL and GWAS 18, 31 . Second, in this work, we investigated predicted gene expression, but FOCUS could generally be applied to other predicted molecular traits with an established role in complex trait etiology (for example, alternatively spliced exons 32, 33 ). For example, several recent works have supporting evidence for splice variation playing an important role in driving risk of schizophrenia 34, 35 . We conclude with several limitations and caveats of our approach. A broad overview of the challenges in TWAS is presented in ref. 10 , and we outline several here. First, our model assumes that complex trait or disease risk is a linear function of steady-state expression levels at causal genes. Several works have demonstrated that risk prediction using a linear combination of predicted steadystate or observed expression levels can outperform standard SNPbased models 34, 36 , which supports a linear model of gene expression impacting complex trait or disease risk. However, higher-order models that capture complex regulatory networks of transcription factors and gene expression may also reflect underlying biology. As reference gene expression data sets grow in size, accurately modeling these assumptions may be possible. Similarly, if risk is mediated through context-specific expression and not steady-state expression levels, then FOCUS will have a loss in performance. Second, while our simulations used the genomic best linear unbiased predictor (GBLUP) 37, 38 throughout for its straightforward implementation, we recommend a cross-validation approach to select the best fitting linear model (for example, GBLUP, Bayesian sparse linear mixed model (BSLMM) 39 ) using the ratio of out-of-sample prediction accuracy normalized by the total SNP-heritability of gene expression, which is implemented in the FUSION framework 1, 34 . Third, when the causal gene is not present in the data, our approach will partially inflate posterior probabilities at tagging genes. We attempt to mitigate this scenario by adding an intercept term to the model and incorporating gene models measured in proxy tissues.
Our simulated results using proxy tissues were performed using a model where causal eQTLs are shared between proxy and relevant tissues 18 . This assumption may be violated in real data if causal eQTLs are tissue specific. Fourth, our approach assumes that the causal tissue is known (for example, adipose tissue causal for lipids [25] [26] [27] [28] ). This cannot always be known for complex traits or diseases with less understood biology. However, recent work has shown that the most relevant (that is, probably causal) tissue for complex traits can be accurately estimated using eQTL data 40 . Coupled with estimation of the causal tissue, we suggest prioritizing genes with high normalized prediction accuracy in related tissues. We note that our results were strongly dependent on sample size in the eQTL reference panel, which is reflected in expression prediction accuracy. We therefore recommend prioritizing eQTL data with sample sizes greater than 100 if possible, and performing inference on genes with robustly non-zero SNP-heritability.
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